Cancer Cachexia

Cancer Cachexia

Global Cancer Cachexia Market to Reach US$3.7 Billion by 2030

The global market for Cancer Cachexia estimated at US$2.5 Billion in the year 2023, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Progestogens Therapeutics, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Corticosteroids Therapeutics segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$943.3 Million While China is Forecast to Grow at 7.5% CAGR

The Cancer Cachexia market in the U.S. is estimated at US$943.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$314.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Cancer Cachexia Market - Key Trends & Drivers Summarized

Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle wasting, and anorexia, significantly impacting the quality of life and survival rates of cancer patients. Unlike general malnutrition, cancer cachexia is driven by complex metabolic changes and inflammation associated with the tumor and the body`s response to it. This syndrome leads to a negative protein and energy balance, which is not easily reversed by conventional nutritional support. Cancer cachexia therapeutics are focused on addressing the complex and debilitating syndrome of cancer cachexia, characterized by severe weight loss, muscle atrophy, and anorexia in cancer patients. This condition significantly impacts patient quality of life, treatment efficacy, and overall prognosis. Unlike general malnutrition, cancer cachexia is driven by a combination of factors including systemic inflammation, metabolic dysregulation, and hormonal changes that lead to a negative protein and energy balance. Traditional nutritional support alone is insufficient, necessitating the development of targeted therapeutics. Current approaches in cancer cachexia therapeutics include anti-inflammatory agents, appetite stimulants, anabolic steroids, and agents that modulate metabolic pathways to preserve muscle mass and improve patient outcomes.

Advancements in the understanding of cancer cachexia`s underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.

The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients` genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.

Select Competitors (Total 50 Featured) -

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Charles River Laboratories International, Inc.
• Aphios Corporation
• Fresenius SE & Co. KGaA
• AbbVie, Inc.
• AVEO Pharmaceuticals, Inc.
• AAVogen, Inc.
• Immuneering
• Caelus Health
• AliveGen USA
• Endevica Bio
• Extend Biosciences

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.